Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support

NCT ID: NCT07073924

Last Updated: 2025-08-12

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 536 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-31
• Study Completion Date: 2028-06-30

Brief Summary

In the U.S., an estimated 3.6 million people who inject drugs (PWID) face a growing yet preventable health crisis, with rising cases of serious injection-related infections (SIRI), including HIV, due to limited access to two high-priority interventions: sterile injection equipment and daily oral HIV pre-exposure prophylaxis (PrEP). Outpatient clinics represent an opportune venue to implement these interventions. Yet most clinical providers in these settings do not currently provide them, contributing to a wide gap between evidence and routine practice. The Prescribe to Prevent HIV (P2PH) trial is a participatory study designed to co-develop and pilot test a set of implementation strategies to support outpatients clinics in offering sterile injection equipment and PrEP with the goal of reducing the risk of HIV and SIRI among PWID.

Detailed Description

In the U.S., 3.6 million people who inject drugs (PWID) face a syndemic of overdose and severe injection related infections (SIRI). Current efforts addressing this crisis remain inadequate as evidence-informed interventions (EIIs) to prevent or reduce SIRI from injection opioid use are not widely implemented and typically limited to syringe service programs. SIRI, which includes bacterial infections (e.g., cellulitis, osteomyelitis, endocarditis), hepatitis C virus, and HIV, significantly increase morbidity, mortality, and costs. HIV, in particular, can be prevented through access to two EIIs: sterile injection equipment and pre-exposure prophylaxis (PrEP). However, PWID in many jurisdictions lack access to these interventions due to shortages of syringe servie programs and clinicians willing to prescribe them. As a result, PWID nationwide have seen rising HIV incidence, threatening the goal of ending the HIV epidemic by 2030. For example, in Pennsylvania, where 90% of PWID lack access to SSPs, acute HIV infections rose by 150% between 2016 and 2019, and SIRI-related hospitalizations increased by 250% since 2010. This wide evidence-to-implementation gap underscores the urgent need for participatory implementation research to integrate these two high-priority EIIs into routine medical practice.

Outpatient clinics represent a missed opportunity to implement these two EIIs. Outpatient clinics, including primary care and Federally Qualified Health Centers, are more accessible and face fewer restrictions than SSPs. While integrating these EIIs in outpatient clinics aligns with federal priorities, prescribing remains uncommon even in addiction treatment contexts. Modeling shows that when outpatient clinics prescribe injection equipment, SIRI-related hospitalizations are reduced by 30%, and when PrEP is prescribed, it increases uptake among PWID. However, gaps remain in how to effectively implement the prescribing of injection equipment and PrEP in these settings.

Prescribe to Prevent HIV, is a participatory study designed to co-create and pilot a tailored implementation strategy bundle for prescribing injection equipment and PrEP in four Pennsylvania Centers of Excellence in Opioid Use Disorders (COEs). The approach combines implementation science with human-centered design, engaging a collaborative of individuals with lived experience, clinicians, and organizations serving PWID throughout all study phases to ensure relevance and sustainability.

Development of the strategy bundle will begin by identifying implementation barriers and facilitators through 24 semi-structured interviews with COE patients, administrators, clinicians, and staff, guided by the Consolidated Framework for Implementation Research and informed by input from a community collaborative of individuals with lived experience. Then, using a human-centered design process, a tailored, practical, and adaptable strategy bundle will be co-created based on findings from the semi-structured interviews, insights from the community collaborative, and input gathered through four focus groups-one each with COE patients, clinicians, staff, and administrators-for implementation across the four COE sites.

A cluster randomized, waitlist-controlled hybrid type 3 implementation-effectiveness pilot trial will then be conducted at the 4 COEs. The trial will assess implementation of the strategy bundle for prescribing injection equipment and PrEP in outpatient clinics. Primary implementation outcomes will include site-level adoption and maintenance, measured by the proportion of clinicians prescribing injection equipment and/or PrEP at the end of the 6-month implementation period (adoption), and at 12 months (maintenance). Secondary outcomes will include patient-level SIRI-related hospitalizations and negative HIV test results.

Conditions

People Who Use Opioids/People With Opioid Use Disorder (OUD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: NONE

Study Groups

Intervention Arm

Immediately gets the intervention of the implementation strategy bundle.

Group Type: OTHER

Implementation strategy bundle

Intervention Type: BEHAVIORAL

The anticipated strategy bundle will include integrated patient-, provider-, and system-level interventions to support sustainable implementation. At the patient level, this may involve education, peer support, and navigation services; at the provider level, training, decision-support tools, and workflow enhancements; and at the system level, policy changes, electronic health record integration, and organizational alignment to promote and maintain prescribing of PrEP and injection equipment.

Waitlist Control Arm

Waits for 6 months with no intervention, then gets the intervention of the implementation strategy bundle.

Group Type: OTHER

Implementation strategy bundle

Intervention Type: BEHAVIORAL

The anticipated strategy bundle will include integrated patient-, provider-, and system-level interventions to support sustainable implementation. At the patient level, this may involve education, peer support, and navigation services; at the provider level, training, decision-support tools, and workflow enhancements; and at the system level, policy changes, electronic health record integration, and organizational alignment to promote and maintain prescribing of PrEP and injection equipment.

Interventions

Implementation strategy bundle

The anticipated strategy bundle will include integrated patient-, provider-, and system-level interventions to support sustainable implementation. At the patient level, this may involve education, peer support, and navigation services; at the provider level, training, decision-support tools, and workflow enhancements; and at the system level, policy changes, electronic health record integration, and organizational alignment to promote and maintain prescribing of PrEP and injection equipment.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

-Adult patients with history of active injection drug use in the past 1 year from the 4 COEs

-Prescribing clinicians (e.g., physicians, advanced practice providers such as nurse practitioners and physician assistants), administrators, medical assistants, and nurses from the 4 COEs

Exclusion Criteria

• Ages <18
• If history of injection drug use >1 year
• Non-English speaking
• Pending or legal action that could prohibit or interfere with participation (Ie. incarceration)
• Residence or discharge to a treatment facility that bans the possession of drug checking supplies
• Acute, severe psychiatric condition in need of immediate treatment.

Clinical Partners:

Pre-implementation interviews (N=12), pre-implementation focus groups (N = 24), post-implementation surveys (N = 80), and post-implementation interviews (N=10)

• Individuals not affiliated with the 4 COEs.
• Staff outside the specified roles (i.e., not prescribing clinicians, administrators, medical assistants, or nurses).
• Students, trainees, or individuals not credentialed in the eligible roles.
• Those on extended leave or not actively working during the study period.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role: collaborator

University of Pittsburgh

OTHER

Sponsor Role: lead

Responsible Party

Raagini Jawa

Assistant Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Raagini Jawa, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

Latterman Family Health Center

Pittsburgh, Pennsylvania, United States

Center for Psychiatric And Chemical Dependency Services

Pittsburgh, Pennsylvania, United States

Internal Medicine Recovery Engagement Program

Pittsburgh, Pennsylvania, United States

UPMC Magee-Womens Hospital

Pittsburgh, Pennsylvania, United States

Countries

United States

Central Contacts

Raagini Jawa, MD, MPH

Role: CONTACT

rjawa@pitt.edu

(412) 232-6275

Facility Contacts

Hannah Scears

Role: primary

scearshe@upmc.edu

(412) 673-5504

Megan Ganung

Role: primary

ganungm2@upmc.edu

(412) 246-5910

Ariana Freund

Role: primary

freundam2@upmc.edu

(412) 232-6275

Ilana Hull, MD

Role: primary

hulli@upmc.edu

412-530-6154

Other Identifiers

K23DA063654

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY25050118

Identifier Type: -

Identifier Source: org_study_id